Flare-up of mucocutaneous leishmaniasis following infliximab discontinuation and antiparasitic therapy in a patient with juvenile idiopathic arthritis

Rheumatology (Oxford). 2023 Apr 3;62(4):e138-e139. doi: 10.1093/rheumatology/keac513.

Authors

Florent Amatore¹, Floriane Lebas¹, Aurélie Haffner², Emmanuel Delaporte¹

Affiliations

¹ Dermatology Department, North Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.
² Pathology Department, Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, Marseille, France.

PMID: 36063056
DOI: 10.1093/rheumatology/keac513

No abstract available

MeSH terms

Antiparasitic Agents / therapeutic use
Antirheumatic Agents* / adverse effects
Arthritis, Juvenile* / drug therapy
Humans
Infliximab / adverse effects
Leishmaniasis, Mucocutaneous* / drug therapy
Treatment Outcome

Substances

Infliximab
Antiparasitic Agents
Antirheumatic Agents